A retrospective cohort study on the effects of Down’s screening markers and maternal characteristics on pregnancy outcomes in preeclampsia

References

• Webster K, Fishburn S, Maresh M, Findlay SC, Chappell LC. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ. 2019;366:l5119. doi:10.1136/bmj.l5119.
   PubMed Web of Science ®Google Scholar
• Hypertensive Disorders in Pregnancy Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Diagnosis and treatment of hypertension and pre-eclampsia in pregnancy: a clinical practice guideline in China2020. Chin J Obstet Gynaeco. 2020, 55 (4), 227–38.
   Google Scholar
• Magee LA, Dadelszen P. State of the art diagnosis and treatment of hypertension in pregnancy. Mayo ClinProc. 2018;93(11):1664–77. doi:10.1016/j.mayocp.2018.04.033.
   PubMed Web of Science ®Google Scholar
• Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. OBSTET GYNECOL. 2020;135(6):e237–e260. doi:10.1097/AOG.0000000000003891.
   PubMed Web of Science ®Google Scholar
• Huang T, Hoffman B, Meschino W, Kingdom J, Okun N. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome. Prenat Diagn. 2010;30(5):471–77. doi:10.1002/pd.2505.
   PubMed Web of Science ®Google Scholar
• Yuan X, Long W, Liu J, Zhang B, Zhou W, Jiang J, Yu B, Wang H. Associations of serum markers screening for Down’s syndrome with pregnancy outcomes: a Chinese retrospective cohort study. CLIN CHIM ACTA. 2019;489:130–35. doi:10.1016/j.cca.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Hourrier S, Salomon LJ, Dreux S, Muller F. Screening for adverse pregnancy outcome at early gestational age. CLIN CHIM ACTA. 2010;411(21–22):1547–52. doi:10.1016/j.cca.2010.06.024.
   PubMed Web of Science ®Google Scholar
• Bartkute K, Balsyte D, Wisser J, Kurmanavicius J. Pregnancy outcomes regarding maternal serum AFP value in second trimester screening. J PERINAT MED. 2017;45(7):817–20. doi:10.1515/jpm-2016-0101.
   PubMed Web of Science ®Google Scholar
• Yazdani S, Rouholahnejad R, Asnafi N, Sharbatdaran M, Zakershob M, Bouzari Z. Correlation of pregnancy outcome with quadruple screening test at second trimester. Med J Islam Repub Iran. 2015;29:281.
   PubMedGoogle Scholar
• Metcalfe A, Langlois S, Macfarlane J, Vallance H, Joseph KS. Prediction of obstetrical risk using maternal serum markers and clinical risk factors. PrenatDiagn. 2014;34(2):172–79.
   Google Scholar
• Hypertensive diseases in pregnancy group, gynecology and obstetrics branch, chinese medical association. Hypertensive diseases in pregnancy group, gynecology and obstetrics branch, chinese medical association. Guidelines for diagnosis and treatment of hypertension in pregnancy. Chin J Obstet Gynaeco. 2015, 50 (10), 721–28.
   Google Scholar
• Chen Y, Xie Z, Wang X, Xiao Q, Lu X, Lu S, Shi Y, Lv S. A risk model of prenatal screening markers in first trimester for predicting hypertensive disorders of pregnancy. Epma J. 2020;11(3):343–53. doi:10.1007/s13167-020-00212-3.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down’s syndrome based on tests performed during the first and second trimesters. N Engl J Med. 1999;341(7):461–67. doi:10.1056/NEJM199908123410701.
   PubMed Web of Science ®Google Scholar
• Santorum M, Wright D, Syngelaki A, Karagioti N, Nicolaides KH. Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13. Ultrasound Obstet Gynecol. 2017;49(6):714–20. doi:10.1002/uog.17283.
   PubMed Web of Science ®Google Scholar
• Gagnon A, Wilson RD. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008;30(10):918–32. doi:10.1016/S1701-2163(16)32973-5.
   PubMedGoogle Scholar
• Lain SJ, Algert CS, Tasevski V, Morris JM, Roberts CL. Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study. BMC MED RES METHODOL. 2009;9:48. doi:10.1186/1471-2288-9-48.
   PubMed Web of Science ®Google Scholar
• Kavak ZN, Basgul A, Elter K, Uygur M, Gokaslan H. The efficacy of first-trimester PAPP-A and free beta HCG levels for predicting adverse pregnancy outcome. J PERINAT MED. 2006;34(2):145–48. doi:10.1515/JPM.2006.026.
   PubMed Web of Science ®Google Scholar
• Keikkala E, Vuorela P, Laivuori H, Romppanen J, Heinonen S, Stenman UH. First trimester hyperglycosylated human chorionic gonadotrophin in serum - a marker of early-onset preeclampsia. PLACENTA. 2013;34(11):1059–65. doi:10.1016/j.placenta.2013.08.006.
   PubMed Web of Science ®Google Scholar
• Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH. Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks’ gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47(6):762–67. doi:10.1002/uog.15849.
   PubMed Web of Science ®Google Scholar
• Wright D, Papadopoulos S, Silva M, Wright A, Nicolaides KH. Serum free beta-human chorionic gonadotropin in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;46(1):51–59. doi:10.1002/uog.14869.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu S, He P, Gu LY, Zhang YZ, Chu XL, Lian JJ, Zhang M. Correlation between preeclampsia and second-trimester maternal serum levels of AFP and free β-HCG. J Wenzhou Med Univ. 2018;48(2):115–18.
   Google Scholar
• Smith GC, Shah I, Crossley JA, Aitken DA, Pell JP, Nelson SM, Cameron AD, Connor MJ, Dobbie R. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. OBSTET GYNECOL. 2006;107(1):161–66. doi:10.1097/01.AOG.0000191302.79560.d8.
   PubMed Web of Science ®Google Scholar
• Yue CY, Zhang CY, Ying CM. Serum markers in quadruple screening associated with adverse pregnancy outcomes: a case-control study in China. Clin Chim Acta. 2020;511:278–81. doi:10.1016/j.cca.2020.10.029.
   PubMed Web of Science ®Google Scholar
• Al KS, O’Reilly EJ, Barrett PM, LD B, Pawley LC, McCarthy FP. Impact of chronic hypertension and antihypertensive treatment on adverse perinatal outcomes: systematic review and meta-analysis. J Am Heart Assoc. 2021;10:e18494.
   Web of Science ®Google Scholar
• Dassah ET, Kusi-Mensah E, Morhe E, Odoi AT. Maternal and perinatal outcomes among women with hypertensive disorders in pregnancy in Kumasi, Ghana. PLOS ONE. 2019;14(10):e223478. doi:10.1371/journal.pone.0223478.
   PubMed Web of Science ®Google Scholar
• Omani-Samani R, Ranjbaran M, Amini P, Esmailzadeh A, Sepidarkish M, Almasi-Hashiani A. Adverse maternal and neonatal outcomes in women with preeclampsia in Iran. J Matern Fetal Neonatal Med. 2019;32(2):212–16. doi:10.1080/14767058.2017.1376643.
   PubMed Web of Science ®Google Scholar
• Shraga Y, Pariente G, Rotem R, Baumfeld Y, Miodownik S, Weintraub AY. Changes in trends over time for the specific contribution of different risk factors for pre-eclampsia. ARCH GYNECOL OBSTET. 2020;302(4):977–82. doi:10.1007/s00404-020-05693-1.
   PubMed Web of Science ®Google Scholar
• Machano MM, Joho AA. Prevalence and risk factors associated with severe pre-eclampsia among postpartum women in Zanzibar: a cross-sectional study. BMC PUBLIC HEALTH. 2020;20(1):1347. doi:10.1186/s12889-020-09384-z.
   PubMed Web of Science ®Google Scholar
• Yogev Y, Langer O, Brustman L, Rosenn B. Pre-eclampsia and gestational diabetes mellitus: does a correlation exist early in pregnancy? J Matern Fetal Neonatal Med. 2004;15(1):39–43. doi:10.1080/14767050310001650707.
   PubMedGoogle Scholar
• Bryson CL, Ioannou GN, Rulyak SJ, Critchlow C. Association between gestational diabetes and pregnancy-induced hypertension. AM J EPIDEMIOL. 2003;158(12):1148–53. doi:10.1093/aje/kwg273.
   PubMed Web of Science ®Google Scholar
• Kalagiri RR, Vora N, Wilson JL, Afroze SH, Raju VN, Govande V, Beeram MR, Kuehl TJ, Uddin MN. Diabetes and pre-eclampsia affecting pregnancy: a retrospective cross-sectional study. J Investig Med. 2018;66(4):728–32. doi:10.1136/jim-2017-000537.
   PubMed Web of Science ®Google Scholar
• Lopez-de-Andres A, Perez-Farinos N, Hernandez-Barrera V, Palomar-Gallego MA, Carabantes-Alarcón D, Zamorano-León JJ, De Miguel-Diez J, Jimenez-Garcia R. A population-based study of diabetes during pregnancy in Spain (2009-2015): trends in incidence, obstetric interventions, and pregnancy outcomes. J CLIN MED. 2020;9:582.
   Web of Science ®Google Scholar
• Voerman E, Santos S, Inskip H, Amiano P, Barros H, Charles MA, Chatzi L, Chrousos GP, Corpeleijn E, Crozier S, et al. Association of gestational weight gain with adverse maternal and infant outcomes. JAMA. 2019;321(17):1702–15. doi:10.1001/jama.2019.3820.
   PubMed Web of Science ®Google Scholar
• Chen CN, Chen HS, Hsu HC. Maternal prepregnancy body mass index, gestational weight gain, and risk of adverse perinatal outcomes in Taiwan: a population-based birth cohort study. Int J Environ Res Public Health. 2020;17(4):1221. doi:10.3390/ijerph17041221.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Vecchi BL, Montico M, D’Ottavio G. First trimester maternal serum PIGF, free beta-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. PLACENTA. 2012;33(6):495–501. doi:10.1016/j.placenta.2012.03.003.
   PubMed Web of Science ®Google Scholar
• Farina A, Rapacchia G, Freni SA, Pula G, Morano D, Rizzo N. Prospective evaluation of ultrasound and biochemical-based multivariable models for the prediction of late pre-eclampsia. Prenat Diagn. 2011;31(12):1147–52. doi:10.1002/pd.2849.
   PubMed Web of Science ®Google Scholar